Search | Clinical Trials Finder

Conditions: Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis, Dislocation, Hip, Femoral Neck Fractures, Trochanteric Fractures, Revision Surgeries
Interventions: G7 Dual Mobility with Vivacit-E bearing, G7 Dual Mobility Longevity bearing; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 6
States / cities: Little Rock, Arkansas • Denver, Colorado • Jersey City, New Jersey + 3 more

Conditions: Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions: Emapalumab; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 0 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 140,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Rheumatoid Arthritis
Interventions: Relaxation response and cognitive behavioral therapy, Relaxation response, RA education; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Juvenile Arthritis
Interventions: Total knee arthroplasty; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Denver, Colorado • Pittsburgh, Pennsylvania • Virginia Beach, Virginia

Conditions: Osteosarcoma, Paget's Disease
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Juvenile Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Rheumatoid Arthritis
Interventions: rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Primary Sjogren's Disease
Interventions: Telitacicept, Placebo; Biological · Drug
Lead sponsor: Vor Biopharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 47
States / cities: Chandler, Arizona • Flagstaff, Arizona • Glendale, Arizona + 41 more

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
Interventions: AMB-05X; Biological
Lead sponsor: AmMax Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more

Conditions: Rheumatoid Arthritis
Interventions: Methotrexate plus ERB-041 for 12 weeks, Placebo for 12 weeks; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 14
States / cities: Largo, Florida • Palm Harbor, Florida • Sarasota, Florida + 11 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Rheumatoid Arthritis
Interventions: BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab; Drug · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 13
States / cities: Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more

Conditions: Achondroplasia
Interventions: Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Sofusa DoseConnect, Enbrel; Device · Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Worcester, Massachusetts • Duncansville, Pennsylvania

Conditions: Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis
Interventions: Total Knee Arthroplasty, Total knee replacement; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 3
States / cities: Greensboro, North Carolina • Austin, Texas • Lakewood, Washington

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: Intercritical Gout
Interventions: Placebo, Rilonacept 80 mg, Rilonacept 160 mg; Other · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more

Conditions: Arthritis, Rheumatoid
Interventions: adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arvin, California + 39 more

Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions: ULSC (1.5 x 10^8 cells/dose), Placebo (no cells); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Search by objective public record fields.

G7 Dual Mobility With Vivacit-E or Longevity PMCF

A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register

Relaxation Response Training for the Treatment of Rheumatoid Arthritis

Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

A Study of Tocilizumab in Patients With Rheumatoid Arthritis

Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)